Menopause Webinar Recording

The FDA Office of Women's Health (OWH) in collaboration with the Center for Drug Evaluation and Research (CDER) Office of Clinical Pharmacology (OCP) hosted a virtual public workshop on October 11, 2023, titled: Menopause: Potential Impact on Clinical Pharmacology and Opportunities for Future Research: https://www.fda.gov/consumers/public-... This workshop was held to discuss the current understanding of the impact of menopause on drug pharmacology and highlight the areas with the greatest need for further research and exploration. Learn more about FDA OWH Public Meetings, Workshops, and Webinars: https://www.fda.gov/OWHmeetings.

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women
▶︎

FDA Expert Panel on Menopause and Hormone Replacement Therapy for Women

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)
▶︎

FDA Direct: Removing Black Box Warnings for HRT (Part 1/2)

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
▶︎

Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims
▶︎

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

Cell Therapies and Tissue-Based Products: Generating Scientific Evidence to Facilitate Development
▶︎

Cell Therapies and Tissue-Based Products: Generating Scientific Evidence to Facilitate Development

193rd Vaccines and Related Biological Products Advisory Committee Meeting
▶︎

193rd Vaccines and Related Biological Products Advisory Committee Meeting

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
▶︎

AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations

Conversations on Cancer: Religious Literacy and Spiritual Care for Patients and Caregivers
▶︎

Conversations on Cancer: Religious Literacy and Spiritual Care for Patients and Caregivers

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees
▶︎

Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees

FDA Grand Rounds: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context & Recent Changes
▶︎

FDA Grand Rounds: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context & Recent Changes

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)
▶︎

FDA Direct: Removing Black Box Warnings for HRT (Part 2/2)

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
▶︎

AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice

CMC Flexibilities for Developing Human Cell and Gene Therapy Products for a BLA
▶︎

CMC Flexibilities for Developing Human Cell and Gene Therapy Products for a BLA

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎

AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers
▶︎

FDA Direct: These 9 Drugs Were Awarded National Priority Vouchers

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy
▶︎

FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications
▶︎

Office of New Drugs Standard Safety Tables and Figures for New Drug and Biologic Applications

Understanding Endpoints in Rare Disease Drug Development
▶︎

Understanding Endpoints in Rare Disease Drug Development

Resources for You and Your Baby
▶︎

Resources for You and Your Baby

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel
▶︎

AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel